Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD PhD, Rebecca L. Olin, MD, Andrew D. Leavitt, MD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1165.

https://doi.org/10.1182/blood-2019-129705

Published: 2019

Journal Articles

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

Shveta Gupta, MBBS, Ayesha Zia, MD, Ravindra Sarode, MD

Blood (2019) 134 (Supplement_1): 4976.

https://doi.org/10.1182/blood-2019-129118

Published: 2019

Journal Articles

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Lorraine Cafuir, MD, En Cheng, Christine L Kempton, MD MSc

Blood (2018) 132 (Supplement 1): 826.

https://doi.org/10.1182/blood-2018-99-110685

Published: 2018

Journal Articles

Idarucizumab for Reversing Anticoagulation in Patients Treated with Dabigatran: Experience in Our Center

Estefania Morente Constatin, MDCINE Resident, Marta Rivas Luque, Pablo Romero Garcia, MDCINE Resident, Maria Almudena Garcia-Ruiz, Manuel Jurado, MD PhD

Blood (2017) 130 (Supplement 1): 4923.

https://doi.org/10.1182/blood.V130.Suppl_1.4923.4923

Published: 2017

Journal Articles

Descriptive Analysis of Idarucizumab (Praxbind ® ) Use in a National Hospital Database

John House, MS, Jessica Franchino-Elder, PhD, Roberta James, MStat, Harold Brown, MBA, Cheng Weng, MD PhD, Mohd Azhar Bin Ahmad, MD MBBC, MRCP

Blood (2017) 130 (Supplement 1): 3714.

https://doi.org/10.1182/blood.V130.Suppl_1.3714.3714

Published: 2017

Journal Articles

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Manuela Albisetti, MD, Arno Schlosser, MSc, Martina Brueckmann, MD, Savion Gropper, MD, Stephan Glund, PhD, Igor Tartakovsky, MD, Leonardo R. Brandão, MD MSc, Paul A Reilly, PhD

Blood (2016) 128 (22): 5010.

https://doi.org/10.1182/blood.V128.22.5010.5010

Published: 2016

Journal Articles

Idarucizumab, a Specific Antidote for Dabigatran, Cross-Reacts with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds

Jawed Fareed, PhD, Larissa Reikensmeyer, Amanda Walborn, BS, Debra Hoppensteadt, PhD, Jeanine M. Walenga, PhD, Eduardo Ramacciotti, MD, Schuharazad Abro, MD, Walter Jeske, PhD, Olivia Bouchard, Ismail Elalamy, MD PhD

Blood (2016) 128 (22): 3836.

https://doi.org/10.1182/blood.V128.22.3836.3836

Published: 2016

Journal Articles

Dabigatran Neutralizing Antobody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications

Zafar Siddiqui, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Mary Lewis, Rohan Rege, Schuharazad Abro, MD, Jawed Fareed, PhD

Blood (2016) 128 (22): 2622.

https://doi.org/10.1182/blood.V128.22.2622.2622

Published: 2016

Journal Articles

Markers of Thromboembolic Risk Were Insignificantly Affected By Either Intraosseous or Intravenous Idarucizumab in a Dabigatran-Anticoagulated Porcine Polytrauma Model

Markus Honickel, MD, Akman Necib, MD, Hugo ten Cate, MD PhD, Rolf Rossaint, MD Prof, Oliver Grottke, MD PhD

Blood (2016) 128 (22): 2623.

https://doi.org/10.1182/blood.V128.22.2623.2623

Published: 2016

Journal Articles

Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers

Joanne van Ryn, PhD, Masahiro Yasaka, MD PhD, Ippei Ikushima, MD PhD, Akiko Harada, PhD, Atsushi Taniguchi, MSc, Susumu Imazu, PhD, Stephen Norris, PhD, Dietmar Gansser, PhD, Joachim Stangier, PhD

Blood (2016) 128 (22): 2627.

https://doi.org/10.1182/blood.V128.22.2627.2627

Published: 2016

Journal Articles

Mechanistic Differences of Prothrombin Complex Concentrate and Idarucizumab in a Trauma Model Under Dabigatran Anticoagulation

Markus Honickel, MD, Joanne van Ryn, PhD, Oliver Grottke, MDPhD

Blood (2015) 126 (23): 1128.

https://doi.org/10.1182/blood.V126.23.1128.1128

Published: 2015

Journal Articles

Prothrombin Complex Concentrate or Idarucizumab in a Multimodal Hemostatic Approach with Tranexamic Acid and Fibrinogen for the Acute Reversal of Dabigatran

Oliver Grottke, MDPhD, Markus Honickel, MD, Rolf Rossaint, MDProf, Till Braunschweig, MD

Blood (2015) 126 (23): 2275.

https://doi.org/10.1182/blood.V126.23.2275.2275

Published: 2015

Journal Articles

Reversal of Trauma-Induced Bleeding and Anticoagulation with a Dabigatran-Specific Antidote (idarucizumab) As Assessed By Shed and Washed Blood Tests in a Pig Model of Supratherapeutic Anticoagulation and Trauma

Oliver Grottke, MD PhD, Markus Honickel, MD, Johanna Schurer, Joanne van Ryn, PhD

Blood (2014) 124 (21): 4268.

https://doi.org/10.1182/blood.V124.21.4268.4268

Published: 2014

Journal Articles

Idarucizumab Fully Restores Dabigatran-Induced Alterations on Platelet and Fibrin Deposition on Damaged Vessels: Studies in Vitro with Circulating Human Blood

Eduardo Arellano-Rodrigo, MD PhD, Irene Lopez-Vilchez, PhD, Patricia Molina, Marcos Pino, Maribel Diaz-Ricart, PhD, Joanne van Ryn, PhD, Gines Escolar, MD PhD

Blood (2014) 124 (21): 2878.

https://doi.org/10.1182/blood.V124.21.2878.2878

Published: 2014

Journal Articles

Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

Stephan Glund, Joachim Stangier, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Gansser, Stephen Norris, Benjamin Lang, Paul Reilly, MD

Blood (2014) 124 (21): 344.

https://doi.org/10.1182/blood.V124.21.344.344

Published: 2014

NARROW

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Idarucizumab for Reversing Anticoagulation in Patients Treated with Dabigatran: Experience in Our Center

Descriptive Analysis of Idarucizumab (Praxbind ® ) Use in a National Hospital Database

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Idarucizumab, a Specific Antidote for Dabigatran, Cross-Reacts with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds

Dabigatran Neutralizing Antobody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications

Markers of Thromboembolic Risk Were Insignificantly Affected By Either Intraosseous or Intravenous Idarucizumab in a Dabigatran-Anticoagulated Porcine Polytrauma Model

Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers

Mechanistic Differences of Prothrombin Complex Concentrate and Idarucizumab in a Trauma Model Under Dabigatran Anticoagulation

Prothrombin Complex Concentrate or Idarucizumab in a Multimodal Hemostatic Approach with Tranexamic Acid and Fibrinogen for the Acute Reversal of Dabigatran

Reversal of Trauma-Induced Bleeding and Anticoagulation with a Dabigatran-Specific Antidote (idarucizumab) As Assessed By Shed and Washed Blood Tests in a Pig Model of Supratherapeutic Anticoagulation and Trauma

Idarucizumab Fully Restores Dabigatran-Induced Alterations on Platelet and Fibrin Deposition on Damaged Vessels: Studies in Vitro with Circulating Human Blood

Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only